| Methods | D: crossover C: unclear B: double WD: 8/40 J: 1‐2‐1 DU: 10w/2x12w (no washout)/‐ | |
| Participants | N: 40/32 D: 27 common, 5 classic migraine C: unclear F: 97% A: 17‐51 years DU: 2‐40 years S: probably university outpatient clinic in Sweden | |
| Interventions | P: 240 mg C: Placebo | |
| Outcomes | R: 11 responders in propranolol phase, no data for placebo F: not reported AU: significantly lower during propranolol phase HI: significantly better during propranolol phase AEs: more frequent in propranolol phase Dropouts‐AEs: 2/40 vs. 2/40 V: + | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.